compounds

Semaglutide testing: methods, impurity profile, salt forms and how published samples fail

short answer

Semaglutide is tested by LC-MS for identity (calculated monoisotopic mass 4111.1154 Da), HPLC for purity and impurities, and a quantitative assay for mg per vial as free base. In Finnrick's public data read on 4 October 2026, 119 of 373 published semaglutide tests failed its default standard, about 32% of classifiable samples. The report should also state the salt form.

Updated Data checked October 2026 5 min read

What a semaglutide test shows

A semaglutide test should answer three questions with three results. LC-MS shows whether the main peptide has semaglutide’s mass. HPLC shows how pure it is and which impurities are present. A content assay shows how many mg of semaglutide, as free base, the vial holds. For vials meant for injection research, endotoxin and sterility are separate tests.

The semaglutide compound page lists the formula (C187H291N45O59), CAS number 910463-68-2 and the calculated ions an LC-MS run looks for: m/z 1371.3791 (3+), 1028.7861 (4+) and 823.2304 (5+). It also lists a recommended panel for each form: freeze-dried vial, liquid vial, pen cartridge and raw powder.

Semaglutide testing methods, step by step

A typical semaglutide test procedure at a lab runs in this order:

Step Method Result
Receipt Photo of the vial, lot and seal logged The vial the report covers
Identity LC-MS: measured mass against 4111.1154 Da Expected and observed mass, error in ppm
Purity HPLC-UV: peak areas at a stated wavelength % area, impurity peaks by retention time
Content Quantitative HPLC against a reference standard mg per vial as free base, % of label
Composition Counter-ion and water (Karl Fischer) TFA or acetate %, water %
Safety Endotoxin (LAL) and Sterility (USP <71>, 14 days) EU/mg and EU/vial; growth or no growth

ICH Q6A says retention time alone “is not regarded as being specific”. That is why identity rests on mass, and purity on the chromatogram. Each method covers a gap in the other.

How semaglutide samples fail in published data

Finnrick, a US platform that publishes HPLC results for samples from anonymous public submissions and its own purchases, is the largest public source. In its public data summary read on 4 October 2026, semaglutide had 373 published tests from 71 vendors, the first on 17 December 2024 and the latest on 20 September 2026. 250 passed, 119 failed and 4 were incomplete. About 32% of classifiable samples failed.

That is a smaller data set than retatrutide or tirzepatide, which each have thousands of published tests and fail rates of about 22% in the same summary. Finnrick’s default standard, Purity Focus, passes a sample at purity of at least 99.5% and a fill within 35% of the label claim. The counts do not say which requirement each sample missed. The guide to peptide fail rates compares all products.

The FDA warns that counterfeit GLP-1 drugs could contain the wrong ingredients, too little, too much or no active ingredient at all. Identity and content tests answer exactly those questions.

Semaglutide impurity profile

A semaglutide impurity shows up as an extra HPLC peak. LC-MS can put a mass on it. Typical mass shifts include +16 Da (oxidation) and +0.98 Da (deamidation).

A technical report from HALO, an HPLC column brand, shows what accurate-mass work looks like. It measured semaglutide at 4111.1027 Da against 4111.1154 Da predicted, an error of 3.09 ppm. In a compounded semaglutide sample, it also found a +12 Da modification at the N-terminal histidine, above the level in the reference product. A report that prints the expected mass, the observed mass and the ppm error lets you check this kind of result yourself.

Mass cannot see everything. Isomers with a D-amino acid in place of an L-amino acid have the same mass as semaglutide. A 2022 study in the Journal of Pharmaceutical and Biomedical Analysis examined these isomers. Only chromatographic separation shows them, so a semaglutide impurity profile needs both HPLC and LC-MS.

Salt forms: semaglutide sodium, acetate and free base

Semaglutide is sold as free base or as a salt, such as semaglutide sodium or semaglutide acetate. The FDA states that these salt forms are different active ingredients from those used in the authorised medicines. For testing, the salt form changes the weight of the powder, not the peptide.

Two things follow for a report:

  • The content result must state its basis. Free base counts only semaglutide. A result on total powder reads higher.
  • The salt form should be stated. A counter-ion test measures the share of TFA or acetate in the powder.

The guide on net peptide content explains why a vial’s powder weighs more than the peptide in it.

Mix-ups: cagrilintide sold as semaglutide

Semaglutide is often sold next to cagrilintide, and in blends with it. The two are easy to tell apart by mass: cagrilintide’s monoisotopic mass is 4406.25 Da, 295 Da above semaglutide. Retatrutide is 617 Da heavier, and tirzepatide 699 Da heavier.

Swaps between these peptides are a known risk, and buyers have reported vials sold as semaglutide that held cagrilintide. Retention time alone can miss such a swap; a mass match does not. If a label is in doubt, a blind GLP-1 identification asks the lab to name the peptide without seeing the label. The cagrilintide testing guide covers the other side of this mix-up.

Compounded semaglutide testing

Compounded semaglutide usually comes as a liquid in a vial or a pen cartridge, with other ingredients. The same core tests apply: identity, purity and content, plus endotoxin and sterility on separate units. Tell the lab the form and the listed ingredients. They change how the lab prepares the sample, and they can add peaks to the chromatogram that are not semaglutide impurities.

Some searches ask about a semaglutide ELISA test. ELISA is an antibody method used mostly on biological samples. It gives no purity result, so it does not replace LC-MS and HPLC for a vial.

What HK Analytical does for semaglutide

We test semaglutide with any mix of identity (LC-MS), purity (HPLC), content per vial, blind GLP-1 identification, endotoxin (LAL), Sterility (USP <71>, 14 days), residual solvents, counter-ion (TFA, acetate), water content (Karl Fischer) and vial-to-vial consistency. Results within days of receipt. Sterility (USP <71>, 14 days) is the one test that takes 14 days, because the method incubates for 14 days. The report states the salt form as received and gives content as free base. Every number comes with its raw data, in a signed record you can check on /verify, with our photo of the vial as received. See the example report or request a quote.

Questions

What is the semaglutide test procedure at a lab?

The lab photographs and logs the vial, then runs LC-MS to match the measured mass to semaglutide, HPLC to measure purity and impurities, and a quantitative assay against a reference standard for mg per vial. Endotoxin and sterility, if ordered, use their own unopened vials. The report gives each result with its method and raw data.

How is semaglutide purity tested?

By HPLC with UV detection. Purity is the semaglutide peak's share of all UV-absorbing peaks at a stated wavelength. It does not include water, salts or counter-ions, and it does not give the mg in the vial. Ask for the chromatogram and the list of impurity peaks.

Can a semaglutide ELISA test check a vial?

An ELISA uses antibodies to detect a molecule, usually in biological samples. It gives no purity figure, and antibodies can bind related molecules. For a vial, LC-MS identity, HPLC purity and a content assay are the tests that answer what is in it and how much.

Does the salt form change a semaglutide test result?

It changes the weight of powder, not the peptide. Sodium or acetate salt adds mass, so a lab must state its basis. A content result as free base counts only the semaglutide itself. A counter-ion test can measure the acetate share of the powder.

Can compounded semaglutide be tested?

Yes. A liquid vial or pen cartridge can be tested for identity, purity, content and, with separate units, endotoxin and sterility. Tell the lab the form and any other ingredients listed, so it can prepare the sample correctly. A test shows what is in the sample; it does not say whether a product is safe to use.

Sources

  1. Finnrick: public data summary (tests, passed and failed by product), read 4 October 2026
  2. Finnrick: methodology and rating standards
  3. HALO: impurity analysis of compounded semaglutide by LC/MS (technical report)
  4. Journal of Pharmaceutical and Biomedical Analysis (2022): D-amino acid isomeric impurities in semaglutide by LC-HRMS/MS
  5. FDA: concerns with GLP-1 drugs used for weight loss (content current as of 1 October 2026)
  6. ICH Q6A: specifications, test procedures and acceptance criteria
  7. PubChem: semaglutide (CID 56843331)

Based on each lab’s public website and sample reports, checked October 2026. Prices, methods and turnaround change; check with the lab before you rely on them. Spotted an error? Write to contact@hkanalytical.com.

Test the vial, not the label.